Fig. 3.

Innate resistance to osimertinib therapy in a patient with high expression of AXL and CDCP1. Panel A shows the positron emission tomography-computed tomography (PET-CT) image of the patient at the time of diagnosis. Panel B shows the treatments the patient received for metastatic EGFR-mutation-positive NSCLC as well as the duration of each treatment. Panel C shows CT images of the patient's lung disease before she received osimertinib, during the time she had a response to osimertinib, when the disease subsequently relapsed at 4 months, and continue to progress after one cycle of chemotherapy. Panel D shows the results of the molecular analysis performed in the patient's baseline tissue biopsy.